Cargando…

Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalities in the Setting of Chronic Statin Treatment

BACKGROUND: Therapeutic intervention with low-density lipoprotein cholesterol-lowering agents known as statins has been demonstrated to reduce cardiovascular risk. However, many patients on statin treatment have persistent dyslipidemia and remain at a high risk of cardiovascular disease. Therefore,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Sifri, Saud N., Almahmeed, Wael, Azar, Sami, Okkeh, Osama, Bramlage, Peter, Jünger, Claus, Halawa, Islam, Ambegaonkar, Baishali, Wajih, Sameh, Brudi, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3882235/ https://www.ncbi.nlm.nih.gov/pubmed/24400085 http://dx.doi.org/10.1371/journal.pone.0084350

Ejemplares similares

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
por: Azar, Sami T, et al.
Publicado: (2014)

Prevalence of dyslipidaemia in statin-treated patients in South Africa: results of the DYSlipidaemia International Study (DYSIS)
por: Raal, Frederick J, et al.
Publicado: (2013)

Body mass index impacts the choice of lipid‐lowering treatment with no correlation to blood cholesterol – Findings from 52 916 patients in the Dyslipidemia International Study (DYSIS)
por: Ferrières, Jean, et al.
Publicado: (2018)

Prevalence of persistent lipid abnormalities in statin-treated patients: Belgian results of the Dyslipidaemia International Study (DYSIS)
por: Devroey, D, et al.
Publicado: (2014)

Prevalence of lipid abnormalities and cholesterol target value attainment in patients with stable coronary heart disease or an acute coronary syndrome in Saudi Arabia
por: Al Sifri, Saud, et al.
Publicado: (2018)

Contemporary data on low-density lipoprotein cholesterol target value attainment and distance to target in a cohort of 57,885 statin-treated patients by country and region across the world
por: Gitt, Anselm K., et al.
Publicado: (2016)

Attainment of cholesterol target values in Greece: results from the Dyslipidemia International Study II
por: Liberopoulos, Evangelos, et al.
Publicado: (2018)

Prevalence of lipid abnormalities and cholesterol target value attainment in Egyptian patients presenting with an acute coronary syndrome
por: Sobhy, Mohamed, et al.
Publicado: (2018)

Prevalence of Lipid Abnormalities and Cholesterol Target Value Attainment in Patients with Stable and Acute Coronary Heart Disease in the United Arab Emirates
por: Al Mahmeed, Wael, et al.
Publicado: (2019)

Do acute coronary events affect lipid management and cholesterol goal attainment in Germany?: Results from the Dyslipidemia International study II
por: Gitt, Anselm K., et al.
Publicado: (2018)

LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China)
por: Zheng, Wen, et al.
Publicado: (2017)

Mixed dyslipidemias in primary care patients in France
por: Laforest, Laurent, et al.
Publicado: (2012)

Dyslipidemia and Rate of Under-Target Low-Density Lipoprotein-Cholesterol in Patients with Coronary Artery Disease in Korea
por: Lee, Sang-Hak, et al.
Publicado: (2019)

Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA)
por: Pettersson, Billie, et al.
Publicado: (2010)

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world
por: Gitt, Anselm K., et al.
Publicado: (2017)

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world
por: Gitt, Anselm K., et al.
Publicado: (2018)

The role of dyslipidemia and statins in venous thromboembolism
por: Ray, Joel G, et al.
Publicado: (2001)

The Pandemic of Coronary Heart Disease in the Middle East and North Africa: What Clinicians Need to Know
por: Manla, Yosef, et al.
Publicado: (2023)

New Drugs for Treating Dyslipidemia: Beyond Statins
por: Ahn, Chang Ho, et al.
Publicado: (2015)

Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East
por: Alshamiri, Mostafa, et al.
Publicado: (2018)

Prevalence and types of persistent dyslipidemia in patients treated with statins
por: Reiner, Željko, et al.
Publicado: (2013)

Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
por: Bak, Keunhyeong, et al.
Publicado: (2023)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia
por: Benes, Lane B, et al.
Publicado: (2016)

Coronary artery disease in Africa and the Middle East
por: Almahmeed, Wael, et al.
Publicado: (2012)

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia
por: Meikle, Peter J., et al.
Publicado: (2015)

Adapting to the COVID-19 Pandemic at a Quaternary Care Hospital in the Middle East Gulf Region
por: Atallah, Bassam, et al.
Publicado: (2020)

Treatment of Dyslipidemia with Statins and Physical Exercises: Recent Findings of Skeletal Muscle Responses
por: Bonfim, Mariana Rotta, et al.
Publicado: (2015)

Apolipoprotein E polymorphisms contribute to statin response in Chinese ASCVD patients with dyslipidemia
por: Zhang, Lei, et al.
Publicado: (2019)

Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan
por: Al Sifri, Saud
Publicado: (2012)

Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
por: Gitt, Anselm K., et al.
Publicado: (2010)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death
por: Huang, Wen-Yen, et al.
Publicado: (2016)

Does Adjuvant Treatment With Ginkgo Biloba to Statins Have Additional Benefits in Patients With Dyslipidemia?
por: Fan, Yu, et al.
Publicado: (2018)

Association of CETP Gene Variants with Atherogenic Dyslipidemia Among Thai Patients Treated with Statin
por: Srisawasdi, Pornpen, et al.
Publicado: (2021)

A Comparison of Statin Treatment Algorithms Based on the ACC/AHA and Philippine Guidelines for Primary Prevention of Dyslipidemia in Statin-Naive Filipino Patients
por: Maglinte, Bayani Pocholo, et al.
Publicado: (2022)

Alarming increase in the prevalence of childhood dyslipidemia in elementary schoolchildren in East of Iran
por: Taheri, Fatemeh, et al.
Publicado: (2014)

Dyslipidemia among rural and urban HIV patients in south-east Malawi
por: Amberbir, Alemayehu, et al.
Publicado: (2018)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_508eovapfp60hvrp0hoeib8t1b